Back to search
FDAFDA · Food and drugs·Recall number D-0434-2023

Heparin Sodium, 25,000USP units per 250 mL, (100 USP units per mL) in 5% Dextrose Injection, 250 mL Excel Container, B.Braun Medical Inc, Bethlehem, PA. 18018-3524 USA. NDC 0264-9587-20.

Published March 15, 2023 · Recall initiated: March 1, 2023

Summary

FDA records drug Class II recall D-0434-2023, published March 15, 2023 and initiated March 1, 2023. Recalling firm: B. Braun Medical Inc; Status: Terminated; Reported quantity: 30672; Lot: Lot J2C017; Expiration: 9/30/2023. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.

Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

Subpotent Drug: low Anti-Factor IIa potency.

What to do

Letter

Get an email if HEPARIN SODIUM IN DEXTROSE has another recall

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Brand
HEPARIN SODIUM IN DEXTROSE
Manufacturer
B. Braun Medical Inc
Distributor
Nationwide in the USA
Lot
Lot J2C017; Expiration: 9/30/2023.
Risk classification
Class II
Area (FDA)
drug
Country
United States

Related recalls

Questions about this recall

Was Heparin Sodium, 25,000USP units per 250 mL, (100 USP units per mL) in 5% Dextrose Injection, 250 mL Excel Container, B.Braun Medical Inc, Bethlehem, PA. 18018-3524 USA. NDC 0264-9587-20. recalled?

Yes. FDA published recall D-0434-2023 on March 15, 2023. Reported hazard: Subpotent Drug: low Anti-Factor IIa potency.

What should I do if I have this product?

Letter

How do I know if my unit is part of the recall?

Compare your product details with the notice. Brand: HEPARIN SODIUM IN DEXTROSE.